Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Operating Leases (2019 - 2025)

Historic Operating Leases for Abeona Therapeutics (ABEO) over the last 7 years, with Q3 2025 value amounting to $4.3 million.

  • Abeona Therapeutics' Operating Leases rose 2504.41% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 2504.41%. This contributed to the annual value of $3.3 million for FY2024, which is 2589.73% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Operating Leases is $4.3 million, which was up 2504.41% from $4.0 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Operating Leases peaked at $9.1 million during Q1 2022, and registered a low of $3.0 million during Q2 2024.
  • Moreover, its 5-year median value for Operating Leases was $4.4 million (2021), whereas its average is $5.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 8671.77% in 2022, then tumbled by 5125.39% in 2023.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Operating Leases stood at $7.6 million in 2021, then dropped by 22.57% to $5.9 million in 2022, then dropped by 24.8% to $4.4 million in 2023, then decreased by 25.9% to $3.3 million in 2024, then skyrocketed by 30.41% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $4.0 million for Q2 2025, and $4.1 million during Q1 2025.